UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer

BioEssays, 2017-05, Vol.39 (5), p.n/a

2017

Volltextzugriff (PDF)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

The New England journal of medicine, 2016-01, Vol.374 (1), p.54-61

2016

Volltextzugriff (PDF)

Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis

Proceedings of the National Academy of Sciences - PNAS, 2014-03, Vol.111 (10), p.3661-3661

2014

Volltextzugriff (PDF)

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

Cell reports (Cambridge), 2017-12, Vol.21 (11), p.3298-3309

2017

Volltextzugriff (PDF)

Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β–SMAD3 pathway in non-small cell lung adenocarcinoma

Proceedings of the National Academy of Sciences - PNAS, 2014-09, Vol.111 (36), p.E3775-E3784

2014

Volltextzugriff (PDF)

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

JCO precision oncology, 2017-01 (1), p.1-13

2017

Volltextzugriff (PDF)

The deficiency of tumor suppressor prep1 accelerates the onset of meis1- hoxa9 leukemogenesis

PloS one, 2014-05, Vol.9 (5), p.e96711

2014

Volltextzugriff (PDF)

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

Scientific reports, 2017-06, Vol.7 (1), p.4204-12, Article 4204

2017

Volltextzugriff (PDF)

Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability

Proceedings of the National Academy of Sciences - PNAS, 2011-07, Vol.108 (29), p.E314-E322

2011

Volltextzugriff (PDF)

Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4795-4795

2018

Volltextzugriff (PDF)

Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3144-3144

2017

Volltextzugriff (PDF)

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Scientific reports, 2017-03, Vol.7 (1), p.44075-44075, Article 44075

2017

Volltextzugriff (PDF)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells

Scientific reports, 2017-04, Vol.7 (1), p.45954-45954, Article 45954

2017

Volltextzugriff (PDF)

Tumorigenesis by Meis1 overexpression is accompanied by a change of DNA target-sequence specificity which allows binding to the AP-1 element

Oncotarget, 2015-09, Vol.6 (28), p.25175-25187

2015

Volltextzugriff (PDF)

Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A145-A145

2018

Volltextzugriff (PDF)

Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1007-1007

2017

Volltextzugriff (PDF)

Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-[Beta]-SMAD3 pathway in non-small cell lung adenocarcinoma

Proceedings of the National Academy of Sciences - PNAS, 2014-09, Vol.111 (36), p.E3775

2014

Volltextzugriff (PDF)

Transcription factor PREP1 induces EMT and metastasis by controlling the TGFß-SMAD3 pathway in non-small cell lung adenocarcinoma

Proceedings of the National Academy of Sciences - PNAS, 2014-09, Vol.111 (36), p.12966-12966

2014

Volltextzugriff (PDF)

Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability

Proceedings of the National Academy of Sciences - PNAS, 2011-07, Vol.108 (29), p.11739-11740

2011

Volltextzugriff (PDF)

The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis: e96711

PloS one, 2014-05, Vol.9 (5)

2014

Volltextzugriff (PDF)

Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9072-9072

2016

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(9)
Humans
(8)
Animals
(7)
Mice
(7)
Multidisciplinary Sciences
(7)
Mutation
(7)
Science & Technology - Other Topics
(7)
Homeodomain Proteins - Metabolism
(6)
Tumors
(6)
Cell Line, Tumor
(5)
Lung Neoplasms - Genetics
(5)
Oncology
(5)
Lung Neoplasms - Drug Therapy
(4)
Neoplasm Proteins - Metabolism
(4)
Pnas Plus
(4)
Biological Sciences
(3)
Carcinoma, Non-Small-Cell Lung - Genetics
(3)
Cell Biology
(3)
Cell Cycle
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

6 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β–SMAD3 pathway in non-small cell lung adenocarcinoma

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

The deficiency of tumor suppressor prep1 accelerates the onset of meis1- hoxa9 leukemogenesis

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation

Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells

Tumorigenesis by Meis1 overexpression is accompanied by a change of DNA target-sequence specificity which allows binding to the AP-1 element

Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC

Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)

Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-[Beta]-SMAD3 pathway in non-small cell lung adenocarcinoma

Transcription factor PREP1 induces EMT and metastasis by controlling the TGFß-SMAD3 pathway in non-small cell lung adenocarcinoma

Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability

The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis: e96711

Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib

Suchergebnisse filtern